OS Therapies Provides Corporate Update
OS Therapies Incorporated (OSTX)
Company Research
Source: Business Wire
Strong cash position relative to monthly burn and cash needs into mid-2026Significant regulatory milestones upcoming in OST-HER2 osteosarcoma programPending acquisition paves the way for commercialization and partnershipsEvaluating strategic options for tunable Antibody Drug Conjugate platform NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today provided a corporate update to the marketplace to contextualize recent positive clinical data, corporate and financial developments.“January 2025 was the most significant month in the Company’s history,” said Paul Romness, MHP, Chairman & CEO of OS
Read more
Impact Snapshot
Event Time:
OSTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OSTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OSTX alerts
High impacting OS Therapies Incorporated news events
Weekly update
A roundup of the hottest topics
OSTX
News
- OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans [Yahoo! Finance]Yahoo! Finance
- OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in HumansBusiness Wire
- OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala PharmaceuticalsBusiness Wire
- OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.MarketBeat
OSTX
Earnings
- 11/15/24 - Miss
OSTX
Sec Filings
- 4/9/25 - Form 8-K
- 4/2/25 - Form 8-K
- 4/2/25 - Form DEFA14A
- OSTX's page on the SEC website